APOE promoter, ACE1 and CYP46 polymorphisms and β-amyloid in Alzheimer's disease

NeuroReport

Volumn 15, Issue 1, 2004, Pages 95-98

  Chalmers, Katy A ^a   Culpan, Doris ^a   Kehoe, Patrick G ^a   Wilcock, Gordon K ^a   Hughes, Anthony ^a   Love, Seth ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

A load; ACE1; Alzheimer's disease; APOE Promoter; CYP46; Polymorphisms

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; DIPEPTIDYL CARBOXYPEPTIDASE; CHOLESTEROL 24 HYDROXYLASE; CHOLESTEROL 24-HYDROXYLASE; STEROID MONOOXYGENASE;

ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; NEUROPATHOLOGY; PARENCHYMA; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK FACTOR; VASCULARIZATION; AGED; COMPARATIVE STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROMOTER REGION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); STEROID HYDROXYLASES;

EID: 3042701772     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200401190-00019     Document Type: Article

References (27)

1. St George-Hyslop PH. Genetic factors in the genesis of Alzheimer's disease. Ann NY Acad Sci 924, 1-7 (2000).
2. Blacker D and Tanzi RE. The genetics of Alzheimer disease: current status and future prospects. Arch Neurol 55, 294-296 (1998).
3. Richard F and Amouyel P. Genetic susceptibility factors for Alzheimer's disease. Eur J Pharmacol 412, 1-12 (2001).
4. Chalmers KA, Wilcock GK and Love S. APOE ε4 favours cerebrovascular over parenchymal deposition of Aβ protein and thereby influences the pathological phenotype of ε4-associated Alzheimer's disease. Neuropathol Appl Neurobiol 29, 231-238 (2003).
5. Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nature Genet 18, 69-71 (1998).
6. Lambert JC, Pasquier F, Cottel D, Frigard B, Amouyel P and Chartier-Harlin MC. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum Mol Genet 7, 533-540 (1998).
7. Laws SM, Hone E, Gandy SE and Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 84, 1215-1236 (2003).
8. Artiga MJ, Bullido MJ, Sastre I, Recuero M, Garcia MA, Aldudo J et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 421, 105-108 (1998).
9. Laws SM, Taddei K, Martins G, Paton A, Fisher C, Clarnette R et al. The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. Neuroreport 10, 879-882 (1999).
10. Lambert JC, Mann D, Goumidi L, Harris J, Amouyel P, Iwatsubo T et al. Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease (erratum appears in Lancet 2001 Apr 28;357(9265):1370). Lancet 357, 608-619 (2001).
11. Lambert JC, Berr C, Pasquier F, Delacourte A, Frigard B, Cottel D et al. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Genet 7, 1511-1516 (1998).
12. Lambert JC, Araria-Goumidi L, Myllykangas L, Ellis C, Wang JC, Bullido MJ et al. Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology 59, 59-66 (2002).
13. Roks G, Cruts M, Bullido MJ, Backhovens H, Artiga MJ, Hofman A et al. The -491 A/T polymorphism in the regulatory region of the apolipoprotein E gene and early-onset Alzheimer's disease. Neurosci Lett 258, 65-68 (1998).
14. Song YQ, Rogaeva E, Premkumar S, Brindle N, Kawarai T, Orlacchio A et al. Absence of association between Alzheimer disease and the -491 regulatory region polymorphism of APOE. Neurosci Lett 250, 189-192 (1998).
15. Kehoe PG, Russ C, McIlory S, Williams H, Holmans P, Holmes C et al. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nature Genet 21, 71-72 (1999).
16. Kehoe PG, Katzov H, Feuk L, Bennet AM, Johansson B, Wiman B et al. Haplotypes extending across ACE are associated with Alzheimer's disease. Hum Mol Genet 12, 1-9 (2003).
17. Hu J, Igarashi A, Kamata M and Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276, 47863-47868 (2001).
18. Lendon CL, Thaker U, Harris JM, McDonagh AM, Lambert JC, Chartier-Harlin MC et al. The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease. Neurosci Lett 328, 314-318 (2002).
19. Wolozin B, Kellman W, Ruosseau P, Celesia GG and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57, 1439-1443 (2000).
20. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides A beta 42 and A beta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98, 5856-5861 (2001).
21. Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thai D, Nicosia F et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 60, 29-35 (2003).
22. Wang JC, Kwon JM, Shah P, Morris JC and Goate A. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease. Neurology 55, 1644-1649 (2000).
23. Desai P, DeKosky ST and Kamboh MI. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci Lett 328, 9-12 (2002).
24. Olichney JM, Hansen LA, Hofstetter CR, Grundman M, Katzman R and Thal LJ. Cerebral infarction in Alzheimer's disease is associated with severe amyloid angiopathy and hypertension. Arch Neurol 52, 702-708 (1995).
25. Casadei VM, Ferri C, Veglia F, Gavazzi A, Salani G, Cattaneo M et al. APOE-491 promoter polymorphism is a risk factor for late-onset Alzheimer's disease. Neurology 53, 1888-1889 (1999).
26. Rebeck GW, Cheung BS, Growdon WB, Deng A, Akuthota P, Locascio J et al. Lack of independent associations of apolipoprotein E promoter and intron 1 polymorphisms with Alzheimer's disease. Neurosci Lett 272, 155-158 (1999).
27. Strozyk D, Blennow K, White LR and Launer LJ. CSF Abeta42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652-656 (2003).